Taken together, our observations in patients with malignancies affecting the lungs bear resemblance to an IRP, which has been described as a more pronounced form of immunosenescence [ 6].
The results show that an IRP results in incremental shopping trips.
In this paper, an IRP method combined with the impact of IL and SL is presented for microgrids planning.
Neither IRP A nor IRP B predicted a differential DrotAA treatment effect in patients with severe sepsis and high risk of death.
Time to death in hospital analyses showed a beneficial DrotAA treatment effect but no additional benefit to knowing IRP A or IRP B genotype (Fig. 2).
Similarly, neither IRP A nor IRP B was predictive of differential DrotAA treatment effects on secondary efficacy endpoints.
Neither IRP A nor IRP B predicted differential response to DrotAA on in-hospital 28-day mortality.
If 750 DAA-treated patients were enrolled and approximately 1,500 matched control patients identified, this trial would have adequate power when testing two hypotheses, IRP A and IRP B, corrected for multiplicity testing.
This international, multicenter, retrospective, nonrandomized, controlled, outcome-blinded, genotype-blinded, and matched-patients study found that neither IRP A nor IRP B predicted differential DrotAA treatment effects on in-hospital mortality through Day 28 in patients with severe sepsis.
Each of the primary analyses, one for IRP A and one for IRP B, will be conducted as a two-sided test with α = 2.5% for an overall, Bonferroni-corrected, type I error rate of 5%.
